IMVT

IMMUNOVANT, INC.

IMVT · CIK 1764013 · Annual (10-K) · Last 6 years

Financial Trends

Revenue
20192025
Net Income−$414M
20192025
Operating CF−$376M
20192025
Free Cash Flow−$377M
20192025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2020↕FY 2019↕
Revenue——————
Cost of Revenue——————
Gross Profit——————
R&D Expense———$0.1B$0.1B$0.0B
SG&A Expense——————
Operating Income——————
Net Income$-0.4B$-0.3B$-0.2B$-0.2B$-0.1B$-0.1B
EPS (Basic)$-2.73$-1.88$-1.71$-1.43——
EPS (Diluted)$-2.73$-1.88$-1.71$-1.43——

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2020↕FY 2019↕
Total Assets$0.8B$0.7B$0.4B$0.5B$0.4B$0.1B
Current Assets$0.8B$0.7B$0.4B$0.5B$0.4B$0.1B
Cash & Equivalents$0.7B$0.6B$0.4B$0.5B$0.4B$0.1B
Total Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B—
Stockholders' Equity$0.7B$0.6B$0.4B$0.5B$0.4B$0.1B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2020↕FY 2019↕
Operating Cash Flow$-0.4B$-0.2B$-0.2B$-0.1B$-0.1B$-0.1B
Investing Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.5B$0.5B$0.1B$0.2B$0.4B$0.1B
← Companies